Pacific Biosciences of Californ (PACB) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.11

Estimate

-$0.13

Surprise

+16.1%

Score today

4.0/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Pacific Biosciences of Californ (PACB) reported a narrower loss than forecast — adjusted EPS of -$0.11 against the -$0.13 estimate (a 16.1% beat on a still-unprofitable quarter).

• PacBio Reports Third-Quarter 2026 Financial Results and Restructuring — fiscal.ai, 2026-11-06
• Piper Sandler Maintains Neutral Rating on PacBio, Raises Price Target — fiscal.ai, 2026-11-06
• Barclays Maintains Underweight Rating on PacBio, Raises Price Target — fiscal.ai, 2026-11-06

TrendMatrix currently rates PACB Sell at 4.0/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +16.1% surprise compares with a +6.3% four-quarter average. Next scheduled report: 2027-02-11.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$2.29

Stop

$2.13

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Devices

Market cap

$755.3M

P/E (fwd)

-5.8

52-week range

$1.07–$3.44

Off 52-week high

33.6%

RSI (14)

60

Volume vs avg

0.29×

Score today

4.0/10